Los Angeles Capital Management LLC Has $21.60 Million Position in Danaher Co. (NYSE:DHR)

Los Angeles Capital Management LLC raised its stake in Danaher Co. (NYSE:DHRGet Rating) by 3.4% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 73,619 shares of the conglomerate’s stock after purchasing an additional 2,427 shares during the period. Los Angeles Capital Management LLC’s holdings in Danaher were worth $21,595,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. JFS Wealth Advisors LLC increased its holdings in shares of Danaher by 30.4% in the fourth quarter. JFS Wealth Advisors LLC now owns 150 shares of the conglomerate’s stock valued at $49,000 after purchasing an additional 35 shares during the last quarter. Rossmore Private Capital raised its stake in Danaher by 0.6% in the 4th quarter. Rossmore Private Capital now owns 6,427 shares of the conglomerate’s stock worth $2,115,000 after purchasing an additional 37 shares in the last quarter. US Asset Management LLC boosted its holdings in Danaher by 0.6% in the 1st quarter. US Asset Management LLC now owns 5,774 shares of the conglomerate’s stock valued at $1,694,000 after purchasing an additional 37 shares during the period. Mairs & Power Inc. grew its position in shares of Danaher by 4.1% during the 4th quarter. Mairs & Power Inc. now owns 959 shares of the conglomerate’s stock worth $316,000 after purchasing an additional 38 shares in the last quarter. Finally, Mutual Advisors LLC increased its holdings in shares of Danaher by 0.7% during the fourth quarter. Mutual Advisors LLC now owns 5,792 shares of the conglomerate’s stock worth $1,906,000 after purchasing an additional 40 shares during the period. 78.42% of the stock is currently owned by institutional investors and hedge funds.

Danaher Stock Up 0.4 %

Shares of NYSE:DHR opened at $290.00 on Friday. The company has a fifty day moving average of $261.98 and a 200-day moving average of $268.32. The company has a market capitalization of $210.96 billion, a PE ratio of 34.16, a price-to-earnings-growth ratio of 2.32 and a beta of 0.86. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.32 and a current ratio of 1.75. Danaher Co. has a 52-week low of $233.71 and a 52-week high of $333.96.

Danaher (NYSE:DHRGet Rating) last issued its quarterly earnings data on Thursday, July 21st. The conglomerate reported $2.76 earnings per share for the quarter, topping the consensus estimate of $2.35 by $0.41. Danaher had a net margin of 20.61% and a return on equity of 18.57%. The company had revenue of $7.75 billion for the quarter, compared to analysts’ expectations of $7.29 billion. During the same quarter in the previous year, the firm posted $2.46 earnings per share. Danaher’s revenue for the quarter was up 7.4% on a year-over-year basis. On average, equities analysts predict that Danaher Co. will post 10.39 EPS for the current fiscal year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, July 29th. Investors of record on Friday, June 24th were paid a $0.25 dividend. The ex-dividend date was Thursday, June 23rd. This represents a $1.00 annualized dividend and a dividend yield of 0.34%. Danaher’s dividend payout ratio is 11.78%.

Analysts Set New Price Targets

DHR has been the subject of a number of analyst reports. UBS Group lifted their price target on shares of Danaher from $297.00 to $323.00 and gave the company a “buy” rating in a research report on Thursday, July 28th. Evercore ISI dropped their price target on shares of Danaher from $320.00 to $280.00 and set an “outperform” rating for the company in a research report on Tuesday, July 5th. Cowen dropped their price target on shares of Danaher to $340.00 in a research report on Friday, July 22nd. Royal Bank of Canada upgraded shares of Danaher from a “sector perform” rating to an “outperform” rating and lifted their price target for the company from $299.00 to $310.00 in a research report on Wednesday, June 1st. Finally, Barclays lifted their price target on shares of Danaher from $290.00 to $310.00 in a research report on Friday, July 22nd. One analyst has rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $328.58.

Insider Buying and Selling

In related news, Director Walter G. Lohr sold 3,906 shares of the business’s stock in a transaction on Friday, July 22nd. The shares were sold at an average price of $273.84, for a total value of $1,069,619.04. Following the sale, the director now owns 12,115 shares of the company’s stock, valued at $3,317,571.60. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, Director Walter G. Lohr sold 3,906 shares of the business’s stock in a transaction on Friday, July 22nd. The shares were sold at an average price of $273.84, for a total value of $1,069,619.04. Following the sale, the director now owns 12,115 shares of the company’s stock, valued at $3,317,571.60. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Joakim Weidemanis sold 12,000 shares of the company’s stock in a transaction on Monday, July 25th. The shares were sold at an average price of $271.13, for a total transaction of $3,253,560.00. Following the sale, the executive vice president now directly owns 74,398 shares in the company, valued at approximately $20,171,529.74. The disclosure for this sale can be found here. 11.20% of the stock is currently owned by insiders.

Danaher Company Profile

(Get Rating)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy.

Recommended Stories

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.